Analysts expect Cytokinetics, Incorporated (NASDAQ:CYTK) to announce sales of $4.83 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Cytokinetics,’s earnings, with the lowest sales estimate coming in at $3.15 million and the highest estimate coming in at $6.50 million. Cytokinetics, posted sales of $33.14 million in the same quarter last year, which suggests a negative year over year growth rate of 85.4%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 15th.

On average, analysts expect that Cytokinetics, will report full year sales of $4.83 million for the current financial year, with estimates ranging from $16.50 million to $26.90 million. For the next year, analysts forecast that the firm will post sales of $33.40 million per share, with estimates ranging from $20.40 million to $44.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Cytokinetics,.

Cytokinetics, (NASDAQ:CYTK) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. The business had revenue of $6.18 million during the quarter, compared to analysts’ expectations of $5.35 million. Cytokinetics, had a negative return on equity of 62.64% and a negative net margin of 172.27%.

A number of analysts recently issued reports on the company. TheStreet cut Cytokinetics, from a “c” rating to a “d” rating in a research report on Friday, October 27th. JMP Securities reissued an “outperform” rating and set a $13.00 price objective (down previously from $17.00) on shares of Cytokinetics, in a research report on Tuesday. They noted that the move was a valuation call. Zacks Investment Research raised Cytokinetics, from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Monday, August 7th. ValuEngine raised Cytokinetics, from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Needham & Company LLC cut Cytokinetics, from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. Cytokinetics, has a consensus rating of “Buy” and a consensus target price of $20.27.

In other news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics, stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $14.71, for a total value of $73,550.00. Following the transaction, the chief executive officer now directly owns 79,785 shares in the company, valued at $1,173,637.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Caryn Gordon Mcdowell sold 13,181 shares of Cytokinetics, stock in a transaction dated Friday, October 6th. The stock was sold at an average price of $15.49, for a total value of $204,173.69. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 178,223 shares of company stock worth $2,639,239. Corporate insiders own 7.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of CYTK. Parametric Portfolio Associates LLC increased its stake in shares of Cytokinetics, by 1.4% in the first quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 189 shares during the period. American International Group Inc. increased its stake in shares of Cytokinetics, by 7.1% in the first quarter. American International Group Inc. now owns 20,852 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 1,380 shares during the period. Teachers Advisors LLC increased its stake in shares of Cytokinetics, by 13.2% in the first quarter. Teachers Advisors LLC now owns 60,326 shares of the biopharmaceutical company’s stock worth $775,000 after purchasing an additional 7,048 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Cytokinetics, by 9.3% in the first quarter. TIAA CREF Investment Management LLC now owns 107,548 shares of the biopharmaceutical company’s stock worth $1,382,000 after purchasing an additional 9,162 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Cytokinetics, by 15.9% in the first quarter. Vanguard Group Inc. now owns 1,949,345 shares of the biopharmaceutical company’s stock worth $25,049,000 after purchasing an additional 267,437 shares during the period. Institutional investors and hedge funds own 71.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/22/cytokinetics-incorporated-cytk-expected-to-announce-quarterly-sales-of-4-83-million.html.

Shares of Cytokinetics, (NASDAQ:CYTK) opened at $8.25 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.60 and a current ratio of 7.60. Cytokinetics, has a 12-month low of $7.00 and a 12-month high of $17.20.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Get a free copy of the Zacks research report on Cytokinetics, (CYTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.